Skip to main content

Table 2 Proportional hazard regression of Progression-free survival

From: HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results

Variables

Univariate

Multivariate

HR [95% CI]

p value

HR [95% CI]

p value

Age ≥ 50 years

1.35 [0.86–2.11]

0.197

  

HR+ (ER+ or PR+)

0.88 [0.57–1.35]

0.548

  

Bone metastasis only

0.58 [0.31–1.10]

0.098

  

HER2 IHC 3+ versus 1+/2+

0.84 [0.47–1.50]

0.564

  

HER2/CEP17 ratio

0.71 [0.58–0.86]

0.001*

0.66 [0.49–0.88]

0.004*

Ki-67 IHC ≥ 50%

4.04 [1.69–9.68]

0.002*

1.49 [0.42–5.28]

0.533

  1. HR hormone receptor, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, CEP17 centromeric probe for chromosome 17, HR hazard ratio, CI confidence interval
  2. * P-value < 0.05
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us